文章摘要

PD-1抑制剂免疫相关不良反应的研究进展

作者: 1,2唐淑慧, 3李丽, 3侯黎莉
1 同济大学医学院,上海 200092
2 上海长海医院肿瘤科,上海 200433
3 上海市第九人民医院护理部,上海 200011
通讯: 侯黎莉 Email: pisces_liz@163.com
DOI: 10.3978/j.issn.2095-6959.2021.03.036
基金: 上海长海医院护理立项课题(2018HLZD03)。

摘要

免疫检查点抑制剂(immune checkpoint inhibitors,ICI)的应用是肿瘤治疗领域的重大突破,是恶性肿瘤患者新的选择和希望。国家食品与药品管理监督局(Chinese Food and Drug Administration,CFDA)批准程序性细胞死亡蛋白-1(programmed cell death protein 1,PD-1)免疫抑制剂用于多种肿瘤的治疗。但是PD-1抑制剂可引起自身免疫毒性,虽然大多数免疫相关不良反应(immune-related adverse events,irAEs)以1~2级为主,但仍有部分患者发生危及生命的3~4级免疫毒性反应。
关键词: 程序性细胞死亡蛋白-1;免疫检查点抑制剂;免疫治疗;免疫相关不良反应

Research progress of immune-related adverse reactions of PD-1 inhibitors

Authors: 1,2TANG Shuhui, 3LI Li, 3HOU Lili
1 School of Medicine, Tongji University, Shanghai 200092
2 Department of Oncology, Shanghai Changhai Hospital, Shanghai 200433
3 Nursing Department, Shanghai Ninth People’s Hospital, Shanghai 200011, China

CorrespondingAuthor: HOU Lili Email: pisces_liz@163.com

Foundation: This work was supported by the Shanghai Changhai Hospital Nursing Project, China (2018HLZD03).

Abstract

The application of immune checkpoint inhibitors (ICI) is a major breakthrough in the field of tumor treatment, and it is a new choice and hope for patients with malignant tumors. Chinese Food and Drug Administration (CFDA) has approved programmed cell death protein 1 (PD-1) inhibitors for the treatment of a a variety of tumors. However, PD-1 inhibitors can cause autoimmune toxicity. Although most immune-related adverse events (irAEs) are in the level of grade 1–2, some patients still have life-threatening immunotoxic response in the level of grade 3–4.
Keywords: programmed cell death protein 1; immune checkpoint inhibitor; immunotherapy; immune-related adverse reactions; nursing management